Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: STN alone Clear all
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional

Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia

NCT01912560
View directory record Official record
Conditions
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
CAT-2003, Placebo, Statin
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Muscle Shoals, Alabama • Los Angeles, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

Statin Therapy in Heart Failure: Potential Mechanisms of Benefit

NCT00233480
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
atorvastatin, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Sep 2, 2026, 7:01 AM EDT
Recruiting Phase 4 Interventional

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

NCT05641753
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product

NCT05234775
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
lerodalcibep
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 2, 2026, 7:01 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

DNA Diagnostic System for Statin Safety and Efficacy

NCT00767130
View directory record Official record
Conditions
Hypercholesterolemia, Myopathy
Interventions
Not listed
Lead sponsor
Genomas, Inc
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
3
States / cities
San Francisco, California • Hartford, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2008 · Synced Sep 2, 2026, 7:01 AM EDT
Recruiting Not applicable Interventional

Correlation of STN-DBS Induced Visuospatial Changes and Freezing of Gait

NCT06994728
View directory record Official record
Conditions
Parkinson Disease, Gait Disorders, Neurologic, Visuospatial/Perceptual Abilities
Interventions
Left STN-DBS on, right STN-DBS off first, Right STN-DBS on, left STN-DBS off first
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

NCT01979601
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
LGT209, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Miami Gardens, Florida • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

NCT01859455
View directory record Official record
Conditions
Hypercholesterolemia, LDL Cholesterol
Interventions
LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 2, 2026, 7:01 AM EDT
Terminated Phase 3 Interventional Results available

Niacin Plus Statin to Prevent Vascular Events

NCT00120289
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Extended release niacin, Simvastatin
Drug
Lead sponsor
Axio Research. LLC
Industry
Eligibility
45 Years and older
Enrollment
3,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
68
States / cities
Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia

NCT00959842
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza
Drug
Lead sponsor
Sanford Research
Other
Eligibility
18 Years to 79 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus

NCT01721460
View directory record Official record
Conditions
Parkinson's Disease, Deep Brain Stimulation Surgery
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Epicatechin on Statins for Mitochondrial Dysfunction and Impaired Exercise Capacity

NCT02490527
View directory record Official record
Conditions
Statin Intolerance
Interventions
Pure epicatechin capsules (50mg), Simvastatin (40mg), Placebo
Dietary Supplement · Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
30 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins

NCT01587365
View directory record Official record
Conditions
Atherosclerosis
Interventions
BMS-962476, Placebo matching with BMS-962476
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2013 · Synced Sep 2, 2026, 7:01 AM EDT
Active, not recruiting Not applicable Interventional

Centralized Prescribing for Statins

NCT05537064
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Non-visit Based Intervention, Visit-Based Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
1,950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 2, 2026, 7:01 AM EDT
Terminated Phase 2 Interventional Results available

STAT-STatin and Aspirin in Trauma

NCT02901067
View directory record Official record
Conditions
Wounds and Injuries, Venous Thromboembolism
Interventions
Aspirin and Rosuvastatin, Placebo (for Aspirin and Rosuvastatin)
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

NCT06191991
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Atorvastatin, ALG-055009, Rosuvastatin
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

NCT00672919
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

NCT04992065
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Not applicable Interventional Results available

Anti-Inflammatory Treatment of Schizophrenia

NCT01514682
View directory record Official record
Conditions
Schizophrenia
Interventions
Anti-inflammatory Combination Therapy, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 2, 2026, 7:01 AM EDT
Recruiting Not applicable Interventional

Use of CereGate Therapy for Freezing of Gait in PD

NCT05292794
View directory record Official record
Conditions
Parkinson Disease, Freezing of Gait, Deep Brain Stimulation
Interventions
CereGate Software; BSN cDBS Programmer; BSN Burst Programmer
Device
Lead sponsor
CereGate Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Redwood City, California • Aurora, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

NCT03545438
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
LIB003
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Results available

DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone

NCT04359823
View directory record Official record
Conditions
Actinic Porokeratosis
Interventions
Lovastatin 2%, 2% Cholesterol Cream, Lovastatin 2% Cream
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Sep 2, 2026, 7:01 AM EDT
Recruiting Not applicable Interventional

OCD LIFU Target Engagement

NCT07558148
View directory record Official record
Conditions
Obsessive Compulsive Disorder (OCD)
Interventions
Low Intensity Focused Ultrasound
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 7:01 AM EDT